![Magnus Nylén](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Magnus Nylén
Direttore/Membro del Consiglio presso
SELECTIMMUNE PHARMA AB (PUBL)
Profilo
Magnus Nylén is currently Director at Hamlet BioPharma AB starting in 2025.
Mr. Nylén is also Director at SelectImmune Pharma AB since 2022.
Additionally, Mr. Nylén has been Owner at Partner Fondkommission AB since 2013.
Mr. Nylén completed undergraduate education at Boston University.
Posizioni attive di Magnus Nylén
| Società | Posizione | Inizio |
|---|---|---|
| SELECTIMMUNE PHARMA AB (PUBL) | Direttore/Membro del Consiglio | 23/11/2022 |
| HAMLET PHARMA AB (PUBL) | Direttore/Membro del Consiglio | 11/03/2025 |
Partner Fondkommission AB
 Partner Fondkommission AB Investment ManagersFinance Offers financial advisory | Corporate Officer/Principal | 01/01/2013 |
Formazione di Magnus Nylén
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
6
Relazioni di 1° grado
4
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Partner Fondkommission AB
Partner Fondkommission AB Investment ManagersFinance Offers financial advisory | Finance |
Hamlet BioPharma AB
 Hamlet BioPharma AB Pharmaceuticals: MajorHealth Technology Engages in the research and development of pharmaceutical products specifically for cancer patients | Health Technology |
SelectImmune Pharma AB
 SelectImmune Pharma AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops and manufactures immune enhancers to complement antibiotics | Health Technology |
